The Association for Molecular Pathology (AMP) 2016 Annual Meeting is held in Charlotte, North Carolina, from November 10-12. The theme of this years meeting will be “Big World. Molecular Medicine. One Community.”
We’re looking forward to being there as the leading global provider of Sample to Insight solutions. Our experts will present our portfolio of consumables, instruments, and bioinformatics at booth #1119 – please stop by for a chat and a demonstration.
On Friday November 11, 9:00 a.m. to 4:00 p.m.* we’re hosting workshops with invited speakers. You can find us in the Product Showcase Theater on the exhibit floor.
*Appointment only demonstrations 4:00 p.m. – 5:00 p.m.
10:00 a.m. – 10:30 a.m.
Enabling precision medicine in oncology through accurate and scalable NGS variant interpretation and reporting with QIAGEN Clinical Insight (QCI™)
Speakers: Helen Fernandes, PhD, Weill Cornell Medicine and Andres Ferreira-Gonzalez, PhD, Virginia Commonwealth University
Next-generation sequencing (NGS) based tests are increasingly being adopted in clinical labs, but there are significant challenges in accurately classifying variants based on levels of evidence and offering actionable insights for healthcare professionals. In this showcase, Dr. Helen Fernandes (Weill Cornell Medicine) and Dr. Andrea Gonzales (Virginia Commonwealth University) will highlight some of the variant interpretation and reporting challenges that clinical testing labs encounter with implementing NGS tests and briefly review their concordance study results using the clinical decision support platform, QIAGEN Clinical Insight (QCI™). They will describe how QCI helps their labs to scale their testing services and improve the actionability of reporting through a comprehensive evidence-based approach and CLIA-CAP compliant reporting guidelines.
12:00 p.m. – 12:45 p.m.
New solutions for oncology and beyond – streamlined testing for CALR and targeted NGS using unique molecular indices
Speakers: Christoph Menzel, PhD, QIAGEN and Fergus Couch, PhD, Mayo Clinic
Advances in molecular analysis have increased understanding of the complex molecular signatures of cancers. In this showcase, Dr. Christoph Menzel (QIAGEN) and Dr. Fergus Couch (Mayo Clinic) will talk about new technologies and applications relevant for oncology research. Dr. Menzel will discuss features of the new CALR qPCR assay from QIAGEN, which offers reliable detection of CALR mutations in exon 9 and identification of Types 1 & 2 in one qPCR run in <4 h. Dr. Couch will introduce a unique PCR chemistry for targeted NGS that improves variant detection and uniformity, and ensures robust enrichment of GC-rich regions.
2:45 p.m. – 3:15 p.m.
Colorectal cancer testing using liquid biopsies – how Clinical Genomics is improving patient outcomes through better recurrence monitoring
Speaker: Lawrence LaPointe, PhD, Clinical Genomics
Analysis of circulating tumor DNA (ctDNA) has the potential to improve detection and monitoring of cancers, with significant impact on patient outcomes. This is especially important for cancers with a high rate of recurrence, such as colorectal cancer where between 30% and 40% of cases recur. However, the only currently available monitoring blood test misses 74% of resectable recurrences. In this showcase, Dr. Lawrence LaPointe (CEO Clinical Genomics) will discuss how his team are working with QIAGEN to harness the power of ctDNA to allow Clinical Genomics to develop a test with twice the recurrence detection rate.
We’re looking forward to seeing you at AMP and discuss how our solutions can benefit your research.
Learn more about QCI
Visit the official event website: AMP 2016